18/03/2015 : THERADIAG reinforces its R&D and production capacities in new state-of-the-art facility

Previous Next Croissy-Beaubourg and Montpellier, March 18, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today it has moved into its new Marne-La-Vallée facility, in the Paris…

Continue Reading18/03/2015 : THERADIAG reinforces its R&D and production capacities in new state-of-the-art facility

11/03/2015 : THERADIAG strengthens its positioning in the oncology theranostics market with its Herceptin® monitoring test receiving CE marking

Croissy-Beaubourg and Montpellier, March 11, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today it has received CE marking for the Herceptin® (trastuzumab) monitoring test that expend…

Continue Reading11/03/2015 : THERADIAG strengthens its positioning in the oncology theranostics market with its Herceptin® monitoring test receiving CE marking